Infliximab and Adalimumab in the Treatment of Fistulizing Crohn's Disease: A Propensity Score-Matched Analysis From the Prospective Persistence Australian National IBD Cohort (PANIC4) Study
The Persistence Australia National IBD Cohort with real-world data of nonhierarchical prescribing of biological agents supports the superiority of infliximab over adalimumab in bio-naive patients with FCD, but did not show a therapeutic difference in bio-exposed FCD. Thiopurine cotherapy was independently associated with improved biological agent persistence in FCD.
Authors
- Sudarshan Paramsothy (ORCID: https://orcid.org/0000-0002-9097-6028)
- John David Chetwood (ORCID: https://orcid.org/0000-0002-8947-9817)
- Rupert W. Leong (ORCID: https://orcid.org/0000-0001-5944-3488)
Institutions
- The University of Sydney (AU)
- Concord Repatriation General Hospital (AU)
- Macquarie University (AU)
Publication Details
- Journal
- The American Journal of Gastroenterology
- Published
- 2024-12-30
- DOI
- https://doi.org/10.14309/ajg.0000000000003271
- Citations
- 1
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.55